SRC and thyroid gland carcinoma: Bosutinib (SKI-606), dasatinib (BMS-354825), saracatinib (AZD0530), KX2-391, and NVP-BHG712 are examples of recently developed Src inhibitors, exhibiting IC50 values ranging from 0.001 to 0.3 μM. In addition to the direct assessment of enzymatic activity, the biological activities of these inhibitors have been tested primarily in cancer disease settings; for example, studies have addressed the ability of Src inhibitors to reduce the progression of breast, colon, and thyroid cancers [147].